Browse diseases

…2Fasano S, Milone A, Nicoletti GF, et al. Precision medicine in systemic lupus erythematosus. Nat Rev Rheumatol. 2023;19(6):331–42. doi: 10.1038/s41584-023-…

…n the pre-competitive setting, the most pressing impediments to lupus drug development. Here, we provide an update on the impactful a…

…he Burkholderia group was the representative bacteria in active lupus with endotoxaemia. The incubation of LPS or bacterial-free DNA …

… rheumatologists from the hospital’s electronic records system. SLE patients who met the 1990 American College of Rheumatology (ACR…

…lusions The roadmap represents a comprehensive landscape of the lupus biomarker field and can be used by the research community as a …

…or trials and what efforts are needed to advance use of PROs in lupus clinical trials.Meeting participants concluded that although PR…

…included pharmacokinetics (PK) and clinical response. Change in lupus biomarkers, including interferon gene signature (IFN-GS), was a…

…fic lupus collaboration. definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016 Sep;75(…

…anifestations of the disease, whilst also addressing underlying lupus pathophysiology upstream of IFN.…

…There is increasing recognition of the need for patient-centred lupus self-management (SM) programmes to improve outcomes. The purpos…

…ental health support, inter-speciality fragmented care, and low lupus awareness among non-specialists. The findings provided a clear …

…learning technologies to support earlier treatment decisions in lupus care.Methods Three meetings with the University of North Caroli…